Floris Fransen
3 Papers
2 Citations
Floris Fransen is an academic researcher. The author has contributed to research in topics: T cell & CD137. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Cecile Geuijen,Paul Tacken,Liang Chuan Wang,Rinse Klooster,Pieter Fokko Van Loo,Jing Zhou,Arpita Mondal,Yao bin Liu,Arjen Kramer,Thomas Condamine,Alla Volgina,Linda Johanna Aleida Hendriks,Hans van der Maaden,Eric Rovers,Steef Engels,Floris Fransen,Renate den Blanken-Smit,Vanessa Zondag-van der Zande,Abdul Basmeleh,Willem Bartelink,Ashwini Kulkarni,Wilfred E. Marissen,Cheng Yen Huang,Leslie Hall,Shane Harvey,Soyeon Kim,Marina Martinez,Shaun O'Brien,Edmund K. Moon,Steven M. Albelda,Chrysi Kanellopoulou,Shaun Stewart,Horacio Nastri,Alexander Berthold Hendrik Bakker,Peggy Scherle,Ton Logtenberg,Gregory Hollis,John de Kruif,Reid Huber,Patrick Mayes,Mark Throsby +40 more
TL;DR: In this paper, a human CD137xPD-L1 bispecific antibody, MCLA-145, was identified through functional screening of agonist-and immune checkpoint inhibitor arm combinations.
Abstract 539: A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137
Patrick Mayes,Paul Tacken,Steve Wang,Pieter-Fokko van Loo,Thomas Condamine,Hans van der Maaden,Eric Rovers,Steef Engels,Floris Fransen,Ashwini Kulkarni,Yao-bin Liu,Arpita Mondal,Leslie Hall,Soyeon Kim,Marina Martinez,Shaun O'Brien,Edmund K. Moon,Steven M. Albelda,Peggy Scherle,Gregory Hollis,Reid Huber,Mark Throsby,Cecile Geuijen +22 more
TL;DR: The clinical evaluation of MCLA-145 as a novel, PD-L1 dependent CD137 agonist immune therapy is supported and an Fc-silenced bispecific IgG1 antibody to CD137 and PD- L1 with monovalent binding specificity to each target is developed.
3
820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells
Paul Tacken,Liang-Chuan Wang,Rinse Klooster,Pieter Fokko Van Loo,Jing Zhou,Arpita Mondal,Yao-Bin Liu,Arjen Kramer,Thomas Condamine,Alla Volgina,Linda Johanna Aleida Hendriks,Hans van der Maaden,Eric Rovers,Steef Engels,Floris Fransen,Renate den Blanken-Smit,Vanessa Zondag-van der Zande,Abdul Basmeleh,Willem Bartelink,Ashwini Kulkarni,Wilfred E. Marissen,Cheng-Yen Huang,Leslie Hall,Shane Harvey,Chrysi Kanellopoulou,Shaun Stewart,Horacio Nastri,Lex Bakker,Ton Logtenberg,Simon Plyte,Patrick Mayes,Mark Throsby,Cecile Geuijen +32 more
TL;DR: The dual anti-cancer activity of MCLA-145 is demonstrated in preclinical models: release of T-cell checkpoint inhibition through PD-L1; and activation and expansion of T cells through CD137, therefore overcoming T- Cell exhaustion and increasing T- cell presence/activity (infiltration) in tumors.